Diabetic retinopathy progression 6 months post-cataract surgery with intravitreous bevacizumab vs triamcinolone: A secondary analysis of the DiMECAT trial.
Muhammad Bayu SasongkoSophie RogersMarios ConstantinouSukhpal S SandhuSanjeewa S WickremasingheSalmaan Al-QureshiLyndell L LimPublished in: Clinical & experimental ophthalmology (2020)
In this study, BVB and TCA groups had a similar, and lower rate of DR progression compared to previous studies where no adjunctive treatment was administered, suggesting that patients with DME may benefit from either intraoperative intravitreous BVB or TCA injection to reduce the risk of DR progression following cataract surgery.